Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antagonist Treatment for Opioid Use Disorder.
Silverman BL, Akerman SC. Silverman BL, et al. Among authors: akerman sc. Am J Med. 2017 Mar;130(3):e117. doi: 10.1016/j.amjmed.2016.08.048. Am J Med. 2017. PMID: 28215953 No abstract available.
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA. Bisaga A, et al. Among authors: akerman sc. Drug Alcohol Depend. 2018 Jun 1;187:171-178. doi: 10.1016/j.drugalcdep.2018.02.023. Epub 2018 Apr 10. Drug Alcohol Depend. 2018. PMID: 29674251 Free article. Clinical Trial.
Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Nunes EV, Bisaga A, Krupitsky E, Nangia N, Silverman BL, Akerman SC, Sullivan MA. Nunes EV, et al. Among authors: akerman sc. Addiction. 2020 Nov;115(11):2188-2190. doi: 10.1111/add.15153. Epub 2020 Jul 16. Addiction. 2020. PMID: 32533597 Free PMC article. No abstract available.
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, Sullivan MA. Kosten T, et al. Among authors: akerman sc. Addict Behav. 2020 Dec;111:106538. doi: 10.1016/j.addbeh.2020.106538. Epub 2020 Jul 3. Addict Behav. 2020. PMID: 32777606 Free article. Clinical Trial.
33 results